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Abstract
We present a novel microfluidic solid-phase extraction (μSPE) device for the affinity enrichment 
of biotinylated membrane proteins from whole cell lysates. The device offers features that address 
challenges currently associated with the extraction and purification of membrane proteins from 
whole cell lysates, including the ability to release the enriched membrane protein fraction from the 
extraction surface so that they are available for downstream processing. The extraction bed was 
fabricated in PMMA using hot embossing and was comprised of 3,600 micropillars. Activation of 
the PMMA micropillars by UV/O3 treatment permitted generation of surface-confined carboxylic 
acid groups and the covalent attachment of NeutrAvidin onto the μSPE device surfaces, which was 
used to affinity select biotinylated MCF-7 membrane proteins directly from whole cell lysates. 
The inclusion of a disulfide linker within the biotin moiety permitted release of the isolated 
membrane proteins via DTT incubation. Very low levels (~20 fmol) of membrane proteins could 
be isolated and recovered with ~89% efficiency with a bed capacity of 1.7 pmol. Western blotting 
indicated no traces of cytosolic proteins in the membrane protein fraction as compared to 
significant contamination using a commercial detergent-based method. We highlight future 
avenues for enhanced extraction efficiency and increased dynamic range of the μSPE device using 
computational simulations of different micropillar geometries to guide future device designs.
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Membrane proteins play key roles in the pathology and physiology of biological cells, 
including regulating the trafficking of ions and solutes in/out of the cell, cell-to-cell 
interactions, and responses to stimuli through surface receptors.1 Specific modifications to 
membrane proteins have been linked to different pathologic states such as cancer, 
neurological disorders, and diabetes.2 Because of the interest in discovering and validating 
disease-specific protein signatures with diagnostic value or discovering new drug targets for 
personalized therapeutics, studies aimed at the identification, characterization, and 
quantification of membrane proteins has increased over the past few years. Most notably, 
several biopharmaceuticals that target membrane proteins are already being utilized for the 
treatment of tumors, lymphomas, and autoimmune diseases.3
Membrane proteins represent approximately one-third of all proteins encoded by the human 
genome.4,5 Yet, only a small fraction of the cell surface proteome has been characterized 
due to analytical challenges including: (i) Low abundance, especially compared to the 
cytosolic proteins;1,6 (ii) low frequency of tryptic cleavage sites in transmembrane 
domains;7 (iii) the heterogeneity of membrane proteins; and (iv) their hydrophobicity 
making them prone to precipitation and aggregation and thus, sensitive to solubilization.7,8 
A number of analytical approaches have been developed to aid in the analysis of membrane 
proteins for example ultracentrifugation,9,10 affinity selection of modified or non-modified 
membrane proteins (antibody- or lectin-based approaches),11,12 two-phase partitioning13,14 
and extraction.15,16 For example, detergent-based membrane protein recovery has been 
demonstrated to be as efficient as >90%; however, this efficiency was demonstrated for a 
mitochondrial membrane protein and recovery of a plasma membrane protein was only 
50%.17 Two important issues are apparent: (i) It is imperative to specifically isolate plasma 
membrane proteins as signal pathways must be stimulated by external interaction;18 and (ii) 
the efficiency of detergent isolation intimately depends on the membrane protein’s 
complexity and hydrophobicity, thereby imparting variability in extraction efficiency.17 In 
general, the majority of detergent methods fail to produce highly pure isolates of membrane 
proteins due in large part to contamination from cytosolic proteins.18
Alternatively, affinity-based isolation of membrane proteins avoids such variability and has 
the potential to target plasma membrane proteins specifically. Approaches utilizing 
antibodies for affinity isolation are challenged by the fact that the appropriate antibodies 
must be available for the necessary targets; one runs the risk of neglecting portions of the 
membrane proteome.19 Recently, improved techniques for the enrichment of membrane 
proteins, both in vivo20 and in vitro,21 have been reported. These include the chemical 
capture of glycosylated membrane proteins,22 silica beads with the appropriate membrane 
protein-specific coatings,23,24 or cell surface biotinylation followed by solid-phase affinity 
extraction using surface immobilized avidin.20,25,26 Zhao et al. employed streptavidin-
coated magnetic beads to enrich plasma membrane proteins that were obtained by lysing 
biotinylated cells from a human lung carcinoma cell line. The method resulted in a 400-fold 
enrichment of plasma membrane proteins relative to the endoplasmic reticulum, which was a 
major contaminant in the membrane fraction, dramatically reduced contamination from 
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other cellular organelles, and as opposed to antibody-based methods, probed all portions of 
the membrane proteome accessible to surface labeling.27
A variety of microfluidic sold-phase extraction devices (μSPE) have been developed that 
employ modification of microchannel solid surfaces with molecular reagents that bear the 
desired affinity agent, the use of polymeric membranes as sorbents, or the incorporation of 
magnetic or silica beads.28,29 The first demonstration of μSPE was performed by 
introducing silica beads into a microchannel for the analysis of amino acids and peptides.29 
Common to these μSPE devices, however, is the difficulty in handling whole cell lysates 
largely because impurities reduce the surface area available for specific isolation of the 
targets and cellular debris can cause clogging (i.e., device failure), especially when utilizing 
packed beads.30–33
We have previously demonstrated a simple and effective method for creating high surface 
area extraction beds that incorporate polymeric micropillars arrayed throughout a fluidic 
channel. The devices were made from thermoplastics and could be molded from metal 
masters in a single step.34–37 This dramatically simplified device production by eliminating 
the need for loading silica beads into small channels or the formation of monoliths. 
However, to the best of our knowledge, μSPE has yet to be applied for the analysis of 
membrane proteins from whole cell lysates. Our previous reports on using these μSPE 
devices were focused on analyzing nucleic acids.34,37
Herein, we present a μSPE device for the enrichment of membrane proteins by affinity 
selection from whole cell lysates. The μSPE device was fabricated by hot embossing into 
poly(methylmethacrylate), PMMA, and contained 3,600 micropillars within an extraction 
bed to provide high surface area. The extraction bed surfaces were covalently decorated with 
NeutrAvidin for selecting biotinylated membrane proteins from a cell lysate while 
minimizing background binding.38–43 Intact MCF-7 breast cancer cells were surface labeled 
with a membrane impermeable sulfo-NHS biotin reagent that ensured only membrane 
proteins were labelled and contained a disulfide linker that could later be cleaved by 
chemical reduction. The whole cell lysate was hydrodynamically passed through the μSPE 
device for extraction of the biotinylated membrane proteins, followed by release by cleaving 
the biotin moiety’s disulfide linker with 1,4-dithiothreitol (DTT). The isolated protein 
fraction was evaluated for membrane protein recovery and potential cytosolic protein 
contamination by a sandwich assay and Western blotting, respectively, both of which 
indicated highly efficient and pure membrane protein recoveries. We highlight the 
importance of membrane protein solubility for successful extraction, the ability to release 
extracted proteins for downstream profiling, and provide avenues for enhanced device 
performance through computational simulations of micropillar geometry and spacing to 
guide future device designs.
Experimental
Reagents and chemicals
Materials used in these studies included PMMA substrates for the fabrication of the μSPE 
devices and 250 μm thick cover plates (Plaskolite, Columbus, OH); 177 μm ID 
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polyetheretherketone (PEEK) tubing (IDEX, Oak Harbor, WA); microcentrifuge tubes 
(Ambion, Foster City, CA); and 4–15% Western blotting gels with PVDF membranes 
(BioRad, Hercules, CA). Micro-90 and sodium dodecyl sulfate (SDS) were obtained from 
Fisher Scientific (Houston, TX). Nuclease-free H2O, reagent-grade isopropyl alcohol (IPA), 
2-(4-morpholino)-ethane sulfonic acid (MES, pH = 5.0), and bovine serum albumin (BSA) 
were used as received and secured from Sigma-Aldrich (St. Louis, MO). 1× phosphate-
buffered saline (PBS, pH = 8.2) was obtained from Life Technologies, Carlsbad, CA. 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), 
sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3′-dithiopropionate (sulfo-NHS-SS-biotin), 
NeutrAvidin, fluorescein-conjugated avidin (FITC-avidin), PageRuler Prestained Protein 
Ladder, the Mem-PER™ Plus Membrane Protein Extraction Reagent Kit, and the Biotin 
Quantification kit were all purchased from Pierce Biotechnology (Rockford, IL). Tris/
Glycine/SDS buffer, β-mercaptoethanol, Tween-20, bromophenol blue, Tris-buffered saline, 
and the BioRad Mini-PROTEAN System were purchased from BioRad (Hercules, CA). 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate (CHAPS), thiourea, 
urea, magnesium acetate, Tris-HCl, glycerol, monoclonal anti-β-actin antibody and L-Lysine 
were also purchased from Sigma Aldrich. The ECL Western blotting detection kit and 
secondary antibody were obtained from GE Life Sciences (Pittsburgh, PA). Monoclonal 
anti-EpCAM antibodies were received from R&D Systems (Minneapolis, MN). MCF-7 cells 
were cultured according to ATCC protocols using MEM Alpha (1X)/insulin/10% FBS (fetal 
bovine serum) (Life Technologies, Carlsbad, CA). TrypLE express (Life Technologies) was 
used to detach cells from the flask surface.
Fabrication and design of the μSPE microfluidic device
A schematic of the fluidic chip is shown in Figure 1 along with a picture of the assembled 
device and SEM images. Fabrication of the microfluidic device involved the following 
major steps: (i) A brass master mold was fabricated by high precision micromilling (Kern 
MMP, Kern Micro- and Feinwerktechnik, Murnau-Westried, Germany). (ii) Hot embossing 
of the microfluidic structures was accomplished using the metal mold master, a HEX03 
machine (JenOptik Mikrotechnik, Jena, Germany) and 3 mm thick PMMA substrates. For 
embossing, the substrate was heated to 180ºC with an applied pressure of 19 kN for 150 s. 
(iii) Post-processing of the microfluidic device included drilling 1 mm diameter sample 
reservoirs, device cleaning with 10% Micro-90, IPA, and DI water, and UV/O3 activation of 
the μSPE device and cover plate using a low pressure Hg lamp (22 mW/cm2 at 254 nm). (iv) 
Thermal fusion bonding of the cover plate to the substrate at 100ºC for 20 min. The 
embossed device consisted of three independent channels (100 μm height, 24 mm long and 
1.4 mm wide) each containing 3,600 micropillars (100 μm height, 100 μm diameter and 50 
μm pillar-to-pillar spacing) that served as the μSPE bed. Each bed had a total surface area of 
1.10 cm2.
NeutrAvidin immobilization
NeutrAvidin was immobilized to the walls and pillars of the μSPE device by covalent 
coupling to pendant carboxylic acid groups generated by UV/O3 activation (as shown in 
Scheme 1 and outlined in Table S1). Briefly, NHS esters were formed by flooding the μSPE 
devices with EDC (6 mg mL−1) and NHS (60 mg mL−1) in 50 mM MES buffer (pH = 5.0) 
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and incubating for 30 min at room temperature. The surface was rinsed with PBS then 
incubated with a 100 μL aliquot of NeutrAvidin (10 μM in PBS).
Cell biotinylation and lysis
MCF-7 cells were washed with ice-cold PBS three times and incubated for 5–10 min in 3 
mL TryplE express. Cells were centrifuged at 300× g for 10 min at 4ºC and resuspended at a 
concentration of 5 × 106 cells/mL in PBS. Eighty μL of sulfo-NHS-SS-biotin (10 mM, 
prepared immediately prior to use in nuclease-free H2O) was added to the cell suspension. 
Cells were incubated at room temperature for 30 min with constant mixing, centrifuged and 
resuspended in lysine (1 mg mL−1 in PBS) to quench the reaction, centrifuged and 
resuspended in ice-cold PBS and centrifuged to obtain a cell pellet. Cell lysis was performed 
by adding 50 μL of 4% CHAPS buffer (4% CHAPS, 7 M urea, 30 mM Tris-HCl, 2 M 
thiourea, and 5 mM magnesium acetate in 100 mL of nuclease-free H2O) to the pellet. 
Dialysis was performed using 7,00 MW cutoff cartridges (BioRad) and carried out overnight 
at 4ºC with two buffer (4% CHAPS) changes to further remove excess biotin.
The extent of biotinylation was quantified using a commercial kit. Briefly, biotinylated 
membrane proteins were added to a solution of avidin and 2-(4′-hydroxyazobenzene)-2-
carboxylic acid (HABA). Displacement of HABA molecules reduced colorimetric 
absorption at 500 nm as measured with an Ultrospec 4000 UV/Vis spectrophotometer 
(Pharmacia Biotech). To aid in the determination of the extent of biotinylation of MCF-7 
membrane proteins, we took a stock solution of biotinylated cells (5 × 106 MCF-7 
biotinylated cells per mL) and labeled the cells with 20 μL FITC-avidin (50 μg mL−1 in 
PBS). The cells were then washed with PBS five times. The cells were lysed, and the lysate 
was evaluated using a fluorometric assay (as detailed below) to determine the concentration 
of FITC-avidin in the cell lysate, which was taken as the concentration of biotinylated 
membrane proteins (2.7:1 avidin:membrane protein stoichiometric ratio). We performed the 
same experiment with a stock solution of cells that were not biotinylated to determine if 
non-specific binding of FITC-avidin occurred. The fluorescence signal for the non-
biotinylated proteins was undetectable, as the FITC-avidin could not bind to the cells 
because they were absent of any biotin moiety.
Membrane protein extraction using the μSPE device
The steps employed in our μSPE device and assay of membrane proteins from whole cell 
lysates are shown in Scheme 1 and outline in Table S1. The cell lysate (5 × 106 MCF-7 
biotinylated cells per mL) was infused into the affinity bed at a volumetric flow rate of 5.0 
μL/min so that biotinylated membrane proteins could be affinity selected by the surface-
confined NeutrAvidin. The surface was then rinsed with a high salt (1 M KCl) and high pH 
(0.1 M Na2CO3, pH = 11.5) wash to remove any loosely-bound cytosolic proteins. In some 
cases, we checked for the affinity selection of biotinylated membrane proteins by counter 
staining with a 100 μL solution consisting of FITC-avidin (50 μg/mL in PBS). Figure S1 
shows fluorescence images of biotinylated MCF-7 cells incubated with fluorescein-labeled 
avidin. The device was rinsed with 100 μL PBS prior to imaging at 20× magnification using 
a fluorescence microscope with excitation at 488 nm and a 300 ms exposure time. The 
microscope was a 200M inverted microscope (Zeiss) that contained a single band filter set 
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(Omega Optical), an XBO 75 Xe arc lamp, and a Cascade 1K EMCCD camera 
(Photometrics). When noted, a proprietary solubilization buffer included with the Mem-
PER™ Plus Membrane Protein Extraction Reagent Kit that was added to the cell lysate 
(initially in 4% CHAPS) prior to infusion.
Membrane protein extraction
Membrane proteins were extracted using a Mem-PER™ Plus Membrane Protein Extraction 
Reagent kit following the manufacturer’s protocol. See the SI for details on this procedure.
Release of captured biotinylated membrane proteins from capture surface
After affinity selection of the biotinylated membrane proteins by the μSPE device, a 300 
mM solution of DTT (in 4% CHAPS) was continuously infused into the SPE bed at a flow 
rate of 5.0 μL/min for 2 h to release the selected membrane proteins by reducing the 
disulfide bond carried in the sulfo-NHS-biotin reagent. Infusion was done in the dark to 
prevent photobleaching of FITC-avidin that was used to determine the efficiency of the 
release process. A total of 100 μL of PBS was then infused into the μSPE device and the 
chip was then imaged as outlined above. We further verified that the extracted proteins were 
indeed released from the affinity bed by measuring the fluorescence of the resulting effluent 
that was collected during the DTT infusion/rinse. A Horiba Jobin Yvon Fluorolog-3 
spectrofluorometer was utilized to form a calibration curve (R2 = 0.9972) of FITC-avidin 
molecules to evaluate the concentration of the eluted biotinylated membrane proteins. The 
entrance and exit slits were set at 5 mm with a photomultiplier tube voltage of 950 V. 
Excitation/emission wavelengths of 491/520 nm were employed.
Protein analysis by Western blotting
Gel runs for the blotting assay employed the BioRad Mini-PROTEAN System. The 
procedure is summarized here. Five mL of 3× Laemmli sample buffer (6% SDS, 30% 
glycerol, 187.5 mM Tris-HCl, 15% β-mercaptoethanol, 0.006% bromophenol blue) was 
added to each protein fraction to prepare them for gel electrophoresis. The fractions were 
heated at 95°C for 5 min, cooled on ice and briefly vortexed before being placed on the gel. 
A 4–15% BioRad precast gel was used along with a PageRuler Prestained Protein Ladder 
that had a molecular weight range of 10–250 kDa. The running buffer (Tris/Glycine/SDS) 
was used to rinse the wells of the gel and the gel was placed in a gel box along with the 
running buffer. Five μL of the PageRuler was added to the well and 50 μL of each protein 
sample was added to the remaining wells. The gel was run for ~35 min at 200 V until the 
dye front could no longer be seen.
A PVDF membrane was prepared by incubating in methanol for 30 s, rinsed briefly in 
ddH2O, and then incubated in ice-cold transfer buffer (20% methanol, 10× Tris/
Glycine/SDS buffer, ddH2O) for 5 min. The gel was removed from the cassette case and 
placed on the PVDF membrane and both were sandwiched together with a transfer cassette. 
The PVDF/gel was placed back into the gel box along with the transfer buffer and run for 70 
min at 250 mA. The membrane was removed from the cassette and rinsed briefly with TBS 
and Tween-20 buffer (0.1% TBST, TBS, Tween-20, ddH2O). The membrane was blocked in 
5% milk (dry milk, 0.1% TBST) for 1 h and then incubated overnight at 4°C with the 
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primary antibody (anti-beta-actin or anti-EpCAM antibodies) suspended in 5% dry milk and 
0.1% TBST. After incubation, the antibody solution was decanted from the membrane. The 
membrane was washed five times for 5 min with the 0.1% TBST buffer and blocked for 5 
min in 5% milk. The membrane was incubated for 1 h at room temperature with the 
secondary antibody (1 μL secondary antibody + 5 mL 5% milk). The membrane was washed 
five times with 0.1% TBST for 5 min and lastly with TBS for 5 min. The membrane was 
placed on a piece of plastic wrap and 2.5 mL of an ECL solution was pipetted over the 
membrane and incubated for 5 min making sure that no part of the membrane dried out. The 
membrane was removed from the ECL solution and excess solution was carefully blotted 
away. The membrane was placed in a plastic sleeve and was exposed to film in a darkroom 
for 30 s and visualized.
Computational fluid dynamics (CFD) simulations and diffusion analysis
Different micropillar geometries were assessed for the isolation of membrane proteins by 
CFD simulations using COMSOL Multiphysics 4.3a. Briefly, three numerically tractable 
model geometries (with only a few rows of micropillars) were tested: (I) Circular pillars 
with radii of 100 μm and pillar-to-pillar spacing of 50.0 μm, (II) diamond pillars with side 
lengths of 20.0 μm and pillar-to-pillar spacing of 20.0 μm, which is similar to a previously 
published device;44 and (III) circular pillars with radii of 10.0 μm and pillar-to-pillar spacing 
of 20.0 μm, which was also tested to determine the effects of pillar shape (circular vs. 
diamond). For all geometries, steady-state laminar velocity fields were solved (see Figure 
S2). Due to computational limits, entire μSPE beds could not be simulated via COMSOL.
The effects of protein diffusion throughout an entire bed’s length were evaluated using an 
analytical solution to Fick’s 2nd law. The time-dependent position probability packet of a 
protein, initially centered between two pillars, was evaluated over a bed’s length, L, 
according to its velocity (extracted from the CFD simulations), and the probability of 
immobilization was taken as the area of the Gaussian packet outside the fluidic channel’s 
walls. We took into account pillar shape by applying a path correction factor, C, to the 
effective length traveled, where Leff = C × L. For a circular pillar, protein travels about a half 
perimeter, yielding C = π/2 ≈ 1.57, and for a diamond, the protein travels about a triangle, 
where there is a smaller effective length given by . These path correction 
factors can be shown to be independent of pillar size or L. Details on this model’s derivation 
and implementation are given in the SI.
Results and Discussion
The μSPE device utilized affinity selection for the specific isolation of membrane proteins 
from whole cell lysates. The affinity selection utilized NeutrAvidin molecules that were 
immobilized within the fabricated μSPE bed. Prior to cell lysis, the intact biological cells 
(MCF-7) were biotinylated. A disulfide moiety was incorporated into the biotinylation 
reagent so that membrane proteins could be released following affinity selection for 
downstream analysis (Scheme 1, Table S1). The reducing agent cleaves the disulfide bond 
and as a result, releases the proteins with an attached residue of 104 g/mole per protein for 
each biotinylated site. In addition, it will reduce disulfides directly within proteins that 
contain such linkages. We will demonstrate both the efficiency of membrane protein 
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extraction from whole cell lysates and the purity of the isolated fractions using this μSPE 
device compared to a detergent-based method. We will also present numerical simulations to 
guide future device designs for improved extraction efficiency and expanded dynamic range.
Solubilization, isolation, and release of biotinylated membrane proteins using the μSPE 
device
We first biotinylated membrane proteins found on MCF-7 cells using a membrane 
impermeable sulfo-NHS biotin reagent containing a disulfide linker. The success of 
biotinylation was confirmed by imaging whole cells labeled with fluorescent FITC-avidin 
(see Figure S1). Cells were then lysed with the whole cell lysate containing both cytosolic 
and biotinylated membrane proteins, which were subsequently passed through the μSPE bed 
that was decorated with NeutrAvidin molecules (Scheme 1, Table S1). NeutrAvidin 
molecules were covalently anchored to the μSPE bed walls through the surface-confined 
carboxylic acids and accessible primary amine groups found on NeutrAvidin. Our group has 
shown that after UV/O3 activation of PMMA, carboxylic acid functional groups are 
generated.45
After removing potential cytosolic contaminants via a high salt and high pH wash, FITC-
avidin was introduced into the μSPE device, which bound to free biotin molecules found on 
the affinity selected proteins (2.7 biotin molecules per membrane protein) in a sandwich-
type assay (Scheme 1, Table S1, and Figure 2A), which permitted direct observation of 
membrane proteins isolated in the μSPE bed. Note that control images (FITC-avidin 
incubated with the μSPE bed without first passing through the cell lysate) indicated minimal 
nonspecific adsorption of the dye-labeled avidin (Figure 2B).
The cell lysate/FITC-avidin sandwich indicated that the membrane proteins isolated in the 
μSPE device were aggregated (Figure 2A) when introduced into the lysis buffer without 
CHAPS, likely due to poor solubilization of the membrane proteins. Solubilization of the 
membrane protein fraction is critical to the μSPE device’s performance. If poorly 
solubilized, membrane proteins may appear as globular deposits on the surface of the μSPE 
bed as shown in Figure 2A. Consequently, cytosolic contaminants could become trapped 
within the deposits as well as lipid contaminants. In addition, extraction may be enabled by 
mixed mechanisms including the specific biotin/avidin interaction and non-specific 
interactions (i.e., hydrophobic/hydrophobic). Under the operation of these non-specific 
interactions, the ability to release isolated membrane proteins by reduction of the disulfide 
moiety may be compromised. To ensure proper solubilization of the membrane proteins, we 
added a solubilization buffer to the 4% CHAPS lysis solution. Processing the cell lysate with 
this solubilization buffer showed much more uniform membrane protein coverage on the 
micropillars with fluorescence visible along all sides of the micropillars as well as the floor 
of the bed (Figure 2C).
The specificity of the membrane protein’s extraction to the NeutrAvidin moieties permitted 
us to reduce the disulfide bond in the biotin linker and release extracted membrane proteins 
(and FITC-avidin molecules from the sandwich complex) from the μSPE bed. After release, 
the FITC-avidin’s fluorescence signal in the μSPE bed returned to the micropillar’s innate 
autofluorescence level (Figure 2D). This loss in fluorescence signal corresponded to an 
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increase in the fluorescence signal of the chip effluent following DTT mediated release 
(Figure 3). The amount of FITC-avidin released into the effluent was used to determine the 
biotinylated protein recovery. After biotinylation, cells were labeled with FITC-avidin, 
washed, lysed, and analyzed with a fluorometer. From ~500,000 cells mL−1, 24.1 pmol 
mL−1 of biotinylated membrane proteins were obtained, which corresponded to ~3 × 107 
biotinylated membrane protein molecules per cell.
With increasing amounts of biotinylated membrane proteins infused through the μSPE bed, 
we observed decreased recovery. The recovery was found to be 88.9 ±2.4% when 0.02 pmol 
of biotinylated membrane proteins were processed. The μSPE data compared favorably to 
recoveries using the detergent-based technique, which recovered ~50% of the membrane 
proteins. Also, recovery via the detergent-based technique is highly variable depending on 
the complexity and hydrophobicity of the membrane protein,17 whereas the efficiency of the 
μSPE bed is dependent on the efficiency of biotinylation rather than hydrophobicity, 
permitting efficient sampling of nearly all membrane proteins.27 When 10.7 pmol was 
processed, only 16.0 ±2.3% of protein was recovered, indicating that the μSPE bed was 
saturated with biotinylated membrane proteins (Figure 3). From Figure 3, the data suggested 
that the maximum amount of protein that could be loaded onto the μSPE bed was 
approximately 1.7 pmol. The theoretical load of immobilized NeutrAvidin, where 
NeutrAvidin is assumed to be a hard sphere with radii of 2.6 nm and is immobilized in a 
close packed hexagonal arrangement,46 the maximum load of NeutrAvidin was calculated to 
be 6.8 pmol. Assuming a 1:1 ratio between NeutrAvidin molecules and biotinylated 
membrane protein, the activated PMMA μSPE bed’s maximum recovery when saturated by 
biotinylated membrane proteins was approximately 25% relative to theoretical calculations. 
This observed difference may be attributed to inefficient UV/O3 activation of the PMMA 
μSPE bed, which we have demonstrated previously.47 Utilization of cyclic olefin copolymer 
(COC) as the fluidic substrate instead of PMMA should improve UV/O3 activation 
efficiency, generating a higher and more uniform carboxylic acid surface density leading to 
higher loads of NeutrAvidin for more efficient recovery of biotinylated material and a larger 
dynamic range.47 Furthermore, the device’s dynamic range can be extended by fabricating 
μSPE beds with smaller and more densely packed pillars, which should increase the 
available surface area and also decrease diffusional distances.37
Purity of membrane protein fractions obtained from the μSPE device and a bench-top 
detergent extraction method
We assessed the purity of the membrane proteins recovered from the μSPE device by 
Western blotting and staining for actin, a highly abundant cytosolic protein (~1 × 108 per 
cell)48 and the epithelial cell adhesion molecule (EpCAM), which is a highly expressed 
membrane protein found in MCF-7 cells (>400,000 per cell49). The presence of an actin 
band in the membrane protein fraction would indicate the presence of cytosolic impurities in 
the membrane protein fraction, while an EpCAM band in this same fraction would indicate 
successful isolation of membrane proteins. These results secured using the μSPE device 
were directly compared to a commercial, detergent-based extraction protocol.
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Membrane and cytosolic protein fractions obtained by the detergent-based technique are 
shown in Figure 4. The Western blot clearly showed the presence of actin with intense bands 
in the total cell lysate (T) and the cytosolic fraction (C). But, there was also the presence of 
actin in the membrane protein fraction (M), suggesting relatively high cytosolic 
contamination when attempting to isolate membrane proteins using the detergent-based 
technique. The same Western blot analysis was also performed after processing an MCF-7 
whole cell lysate using the μSPE bed. In this case, no actin band was observed in the 
Western blots for the membrane protein fraction. We subsequently stained for EpCAM and 
confirmed the presence of this membrane protein in the fraction isolated via μSPE. 
Considering the abundance of actin relative to EpCAM, the absence of an actin band clearly 
indicated highly pure membrane protein fractions isolated using μSPE.
Computational modeling of micropillar geometry and membrane protein extraction
To further increase the device’s dynamic range and the efficiency for recovering membrane 
proteins, we conducted computation modeling to guide future designs of the μSPE device. 
Specifically, we were interested in investigating how micropillar geometry and spacing may 
affect the efficiency of membrane protein extraction. The simulations were carried out using 
computational fluid dynamics (CFD) with COMSOL Multiphysics and a numerical analysis 
using Fick’s 2nd law governing diffusion. For CFD simulations, numerically tractable 
geometries composed of only a few staggered rows of micropillars (as opposed to the 
thousands occupying the μSPE bed), were tested. Three different geometries were evaluated: 
(I) Circular micropillars with the same dimensions as the μSPE device shown in Figure 1; 
(II) small, diamond micropillars (20 μm side length) spaced by 20 μm, which is similar to a 
device we have used previously;37,50 and (III) circular micropillars with analogous 
dimensions as geometry II (20 μm pillar radii, 20 μm pillar-to-pillar spacing). The steady-
state velocity fields (shown in Figure S2) were comparable in all geometries, which is not 
surprising given the low Reynolds number for these devices. Additionally, the velocities 
between the pillars were nearly uniform regardless of pillar position, indicating uniform 
protein distribution throughout all μSPE beds. Average linear velocities through the beds 
were extracted from the CFD simulations to assess diffusion occurring on the length scale of 
the entire μSPE bed, which would be numerically intractable to model using CFD 
simulations alone.
For cases with diffusion, a protein with its initial position centered between two pillars and 
described by a Gaussian probability packet that spreads over time according to its diffusion 
constant was propagated over a time scale proportional to its velocity and effective path 
length through the μSPE bed. The normalized area of the Gaussian packet outside the 
bounds of the fluidic pathways (overlapping with a micropillar itself) was taken as probable 
extraction onto a micropillar’s surface. The results for several flow rates through geometries 
I–III are shown in Figure 5. Two sets of results are shown; the first simulation less 
accurately assumes that the protein travels in a straight path through the bed (ignoring 
micropillars altogether), while the second uses an effective bed length corrected by a factor 
(C), which included the distance required to circumnavigate a micropillar that was 
dependent on the micropillar’s shape. Further details are provided in the SI.
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As the flow rate increased, the probability of protein interaction with the pillar surface (Pi) 
decreased for all geometries. However, this dependency was less pronounced for Geometries 
II and III, which only had 20 μm pillar-to-pillar spacing and required less diffusion to occur 
for protein-pillar interaction. Comparison between Figures 3 and 5 indicated good 
agreement (an experimental recovery of 88.9 ±2.1% vs. 68.0% theoretically), especially 
because this diffusion model only considered a protein centered exactly between two pillars, 
a worst-case scenario requiring the largest transverse diffusion to occur for protein-pillar 
interaction, whereas well-solubilized proteins are homogeneously distributed throughout the 
interstitial space between the pillars. The model indicated that smaller pillar-to-pillar 
spacing, regardless of the micropillar shape, should increase membrane protein recovery.
Lastly, inclusion of the path correction factor increased the time for diffusion and improved 
the probability of extraction and more so for circular pillars compared to diamond-shaped 
pillars, which have a larger perimeter (C = π/2 ≈ 1.57) than diamond pillars 
( ). However, this effect was minor when comparing Geometries II and III (an 
improvement of only 0.6% at 10 μL min−1 infusion) as the small pillar-to-pillar spacing 
induced higher recovery even when the path correction factor was ignored. Thus, future 
designs, especially those integrated with downstream protein separation and analysis, should 
employ μSPE beds with smaller, more densely packed pillars with smaller pillar-to-pillar 
spacing than that employed herein. This would also result in a higher surface area to 
improve recovery and the dynamic range.
Conclusion
A polymer microfluidic chip was designed, fabricated, and evaluated for the solid-phase 
extraction and purification of membrane proteins from whole cell lysates. The device 
contained 3,600 micropillars that provided a higher surface area for protein extraction 
compared to an open channel of the same dimensions, could be replicated from a mold 
master in a single step, and did not require complex post-processing steps for its operation, 
such as the addition of functionalized beads or the chemical formation of monolithic 
supports.
MCF-7 cells were biotinylated with a membrane impermeable reagent and then lysed. 
Whole cell lysates were processed through the μSPE device, where biotinylated membrane 
proteins were specifically selected using immobilized NeutrAvidin. Inclusion of a disulfide 
moiety within the biotinylation reagent framework permitted release of the extracted 
membrane proteins following reduction of the disulfide linkage. The μSPE assay produced 
significantly lower levels of cytosolic protein contamination compared to a commercially-
available detergent method. Furthermore, we were able to recover ~89% of biotinylated 
membrane proteins from a whole cell lysate. Thus, we demonstrated efficient recovery of 
highly pure fractions of membrane proteins that can be released for downstream analysis. 
The μSPE device comprised a simplified workflow to allow for the generation of 
information regarding a small but important portion of the proteome that is typically difficult 
to analyze.18,51,52 We also provided several avenues to increase both the recovery and 
dynamic range of the device including polymer choice and computational simulations 
indicating the benefits of small circular pillars with reduced pillar-to-pillar spacing.
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The results secured using this μSPE device for the extraction and purification of membrane 
proteins will provide an attractive approach that can be integrated to other devices for future 
studies directed toward determining potential therapeutic targets or selection agents for 
various cell types due to the higher purity membrane protein fractions isolated and the 
ability to process small numbers of cells. For example, we have previously demonstrated 
microfluidic cell isolation units for isolating extremely rare, circulating tumor cells from 
whole blood patient samples with high purity.53,54 These microfluidic devices can be 
coupled to the μSPE device detailed in this manuscript to isolate plasma membrane proteins 
from these rare cells for downstream multi-dimensional electrophoresis for protein 
separation,55,56 solid-phase proteolytic digestion57 and mass spectrometry for protein 
identification.58–60 We are currently developing an integrated system incorporating these 
previously described devices with the μSPE device for top-down proteomic analysis of 
membrane proteins from rare cells, such as circulating tumor cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) Illustration of the topographical layout of the PMMA μSPE device showing three 
separate beds with micropillars used for the affinity capture of biotinylated membrane 
proteins. (B) SEM image of the μSPE capture bed. (C) A photograph of the assembled 
PMMA μSPE device.
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(A) Fluorescence image of poorly solubilized membrane proteins isolated on the μSPE 
device. (B) Control image of the μSPE bed incubated with FITC-avidin without first 
infusing the cell lysate showing minimal nonspecific adsorption of the dye-labeled avidin 
complex. (C) Fluorescence image of well-solubilized membrane proteins isolated on the 
μSPE bed. (D) μSPE bed after release of membrane proteins with DTT.
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The recovery of biotinylated MCF-7 membrane proteins loaded onto the μSPE device. The 
total amount of protein (pmol) before and after μSPE purification was estimated from 
fluorescence data, which measured proteins that were biotinylated. Error bars in the graph 
represent standard deviations from three replicate runs.
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Actin Western blots demonstrating for detergent-based extraction and the μSPE extraction 
using actin as the model cytosolic protein. Also shown is the EpCAM Western blot of the 
membrane protein fraction eluted from the μSPE device to show that there were membrane 
proteins from the MCF-7 cell lysate in the fraction. For these Western blots, approximately 
5 × 106 MCF-7 cells were lysed and taken to a total volume of 1.0 mL. This lysate was 
either directly loaded onto the gel (30 μL) for Western analysis or diluted ~1000-fold with 
100 μL processed using the μSPE device. Due to the limited bed capacity of the μSPE 
device, the EpCAM band intensity was much weaker for the μSPE device compared to 
direct processing of the lysate.
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Illustration of the path correction factor (C) for both circular and diamond shaped 
micropillars. The probability of protein-post interaction (Pi) for Geometries I–III, both with 
(solid black or white, where ) and without (solid grey, where C = 0) the path 
correction factor applied to the μSPE bed’s length.
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Overview of the on-chip extraction/purification of biotinylated membrane proteins from cell 
lysates using the μSPE device. (A) Micropillar activation and NeutrAvidin immobilization; 
(B) whole cell lysate infusion where the biotinylated membrane proteins are affinity 
captured while contaminating cytosolic proteins are eluted; and (C) FITC-avidin addition 
used to label unreacted biotin of selected membrane proteins followed by disulfide bond 
reduction releasing either FITC-avidin labeled membrane proteins or unlabeled membrane 
proteins from the μSPE bed. Symbols are defined in the legend.
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